Skip to main content

COVID Studies

Listen COVID Study

A new study exploring the effectiveness of a long Covid intervention is looking for people living with the condition to take part.

The Long COVID Personalised Self-management support co-design and Evaluation (LISTEN) study will evaluate the effectiveness of a new personalised support programme, co-designed by people living with long Covid.

Participants will be randomly selected into two groups, one receiving the LISTEN support package, which will involve a resource book and up to six, one-to-one video or telephone call support sessions, with the other group receiving their usual local NHS services.

The study is open to anyone over 18 years of age who has been experiencing long Covid symptoms for 12 weeks or more and has consulted with their GP.

Carol from our Patient & Public Involvement group says “I’m one of the people involved in the LISTEN trial and if you take part, you may read more about my story and those of other people. I can’t read a book at the moment, but the handbook is nice and easy to access and I’m sure you’ll find it useful. Don’t be put off by the thought of any forms or telephone calls, the people at LISTEN really understand and individualise the approach to what works for you. My advice would be, don’t miss this opportunity, grab it, and don’t delay. I wish this had been around for me when I was earlier in my journey, but I’m very proud to be part of the project now.”

The LISTEN study is now open for recruitment. Please visit for more information and to register your interest in taking part.



Wales is taking part in the UK PANORAMIC clinical trial, which aims to find new antiviral treatments for people with COVID-19 that can be taken at home.

To be eligible to join the trial you will need to have a positive test (PCR or LFT) and COVID-19 symptoms starting in the last 5 days. The trial is open to people aged 50 or over, or 18-49 years with an underlying health condition.

You can register for the trial at

For full details, visit



The PRINCIPLE trial aims to find treatments that reduce hospital admission and improve symptoms for people with COVID-19.

You could be eligible to join if:

  • You have had symptoms for fewer than 15 days
  • A continuous new or high temperature or loss of/ change in normal sense of taste or smell
  • OR have a positive test for SARS-COV-2 infection with COVID-19 symptoms in the past 14 days
  • You are aged 50-64 with a pre-existing illness
  • You are aged 65 or above

The PRINCIPLE Trial is entirely remote. You can participate from the comfort of your own home from anywhere in the UK with no face-to-face visits required. The trial team and your own GP will be available for you to contact throughout.

Find Out More

***PRINCIPLE is still open to those who have received one of the covid-19 vaccines



This national clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19.


Peter Horby, Professor of Emerging Infectious Diseases and Global Health

A range of potential treatments have been suggested for COVID-19 but nobody knows if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive. The RECOVERY Trial is currently testing some of these suggested treatments: 

  • Low-dose Dexamethasone  (now only recruiting children)
  • Colchicine (commonly used anti-inflammatory)
  • Tocilizumab (an anti-inflammatory treatment given by injection)
  • Convalescent plasma (collected from donors who have recovered from COVID-19 and contains antibodies against the SARS-CoV-2 virus)
  • Regeneron’s antibody cocktail (a combination of monoclonal antibodies directed against coronavirus)
  • Aspirin (commonly used to thin the blood).  

Data from the trial are regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. Please see our news page for results that RECOVERY has already found. The RECOVERY Trial team will constantly review information on new drugs and include promising ones in the trial.